Bone Health on Long-Term Steroids: Preventing Glucocorticoid-Induced Osteoporosis

Why Glucocorticoids Destroy Bone Faster Than You Expect

Glucocorticoids like prednisone, methylprednisolone, and dexamethasone attack bone through multiple mechanisms simultaneously, making them uniquely destructive to the skeleton. Bone loss is rapid, dose-dependent, and partially irreversible, with fractures sometimes occurring before a DEXA scan shows osteoporosis.

Corticosteroids suppress osteoblast function and accelerate osteoblast apoptosis, directly reducing new bone formation. They also extend the lifespan of osteoclasts, the cells that break down bone, tipping the remodeling balance toward net loss [1]. A 2018 meta-analysis in the Journal of Bone and Mineral Research found that patients taking 7.5 mg/day of prednisone for six months lost an average of 5.3% of lumbar spine bone mineral density (BMD) [2].

Beyond direct skeletal effects, glucocorticoids reduce intestinal calcium absorption, increase renal calcium excretion, and suppress gonadal hormone production. This triple hit on calcium homeostasis means that even patients who take calcium supplements may remain in negative calcium balance. Glucocorticoids also suppress growth hormone and insulin-like growth factor 1 (IGF-1), removing another anabolic signal the skeleton depends on [3].

The fracture risk from glucocorticoids rises before BMD drops enough to meet the T-score definition of osteoporosis. A landmark study published in the Journal of Bone and Mineral Research demonstrated that vertebral fractures in glucocorticoid users occurred at T-scores 0.5 to 1.0 standard deviations higher than in patients with primary osteoporosis [4]. This means standard DEXA thresholds underestimate true fracture risk in steroid users. Five mg/day of prednisone increases vertebral fracture risk by 2.6-fold and hip fracture risk by 1.6-fold within three to six months of starting therapy [5].

Who Needs Screening and When to Start

Every adult expected to take glucocorticoids at 2.5 mg/day prednisone-equivalent or higher for three months or longer should undergo fracture risk assessment, according to the 2022 American College of Rheumatology (ACR) guidelines for GIOP prevention and treatment [6]. This is not optional. It applies regardless of age, sex, or underlying diagnosis.

The assessment starts with a clinical fracture risk evaluation using the FRAX tool (Fracture Risk Assessment Tool), which should be adjusted upward for glucocorticoid dose. Standard FRAX includes a binary yes/no for glucocorticoid use, but this underestimates risk for patients on medium or high doses. The ACR recommends multiplying the FRAX major osteoporotic fracture probability by 1.15 for doses of 7.5 mg/day or more and multiplying the hip fracture probability by 1.2 [6].

Baseline DEXA scanning of the lumbar spine and hip is recommended for all patients initiating long-term glucocorticoid therapy. Vertebral fracture assessment (VFA) or lateral thoracolumbar spine imaging should be performed in patients over 65, patients over 40 with significant risk factors, or any patient with height loss greater than 1.5 inches [7].

Risk stratification under the ACR guidelines places patients into three categories: low (FRAX major osteoporotic fracture <10% and hip fracture <1%), moderate (major osteoporotic fracture 10 to 19% or hip fracture 1 to 3%), and high (major osteoporotic fracture 20% or higher, hip fracture 3% or higher, T-score at or below -2.5, or prior fragility fracture). Treatment recommendations escalate with each tier.

First-Line Prevention: Calcium, Vitamin D, and Lifestyle

All patients on glucocorticoids should optimize calcium and vitamin D intake, regardless of their fracture risk category. The ACR conditionally recommends 1,000 to 1,200 mg of elemental calcium daily (diet plus supplements) and 600 to 800 IU of vitamin D daily, with dose adjustments to maintain serum 25-hydroxyvitamin D above 30 ng/mL [6].

Calcium carbonate requires gastric acid for absorption and should be taken with meals. Calcium citrate is absorbed independently of gastric pH, making it the better choice for patients on proton pump inhibitors or those with achlorhydria. Split dosing (500 to 600 mg per dose) improves absorption compared to single large doses [8].

Lifestyle modifications matter. Weight-bearing exercise (walking, stair climbing, resistance training) stimulates osteoblast activity and counters the muscle weakness that glucocorticoids cause. Fall prevention strategies become especially important because glucocorticoids cause proximal myopathy, increasing fall risk independently of bone density changes. Smoking cessation and limiting alcohol to two or fewer drinks daily are conditionally recommended [6].

These measures alone are insufficient for moderate or high-risk patients. They form the foundation on which pharmacologic therapy is built, not a substitute for it.

Pharmacologic Treatment: Choosing the Right Bone-Protective Drug

For patients at moderate-to-high fracture risk on long-term glucocorticoids, the 2022 ACR guidelines conditionally recommend pharmacologic therapy. The choice depends on fracture risk severity, patient age, reproductive status, and treatment duration.

Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are the most commonly prescribed first-line agents for GIOP. The Glucocorticoid-Induced Osteoporosis Skeletal Endurance (GIOSE) trial demonstrated that alendronate increased lumbar spine BMD by 2.9% over 48 weeks in glucocorticoid-treated patients compared to 0.7% with placebo [9]. Risedronate showed a 61% reduction in vertebral fracture risk over 12 months in patients on at least 7.5 mg/day prednisone [10]. Patients must take oral bisphosphonates on an empty stomach with a full glass of water and remain upright for 30 minutes to prevent esophageal irritation.

IV zoledronic acid (5 mg annually) is preferred for patients who cannot tolerate oral bisphosphonates or who have adherence concerns. A head-to-head trial comparing zoledronic acid to risedronate in GIOP found that zoledronic acid produced significantly greater BMD increases at the lumbar spine (4.1% vs. 2.7% at 12 months) [11].

Teriparatide (20 mcg daily subcutaneous injection) is the preferred agent for patients at high fracture risk, especially those with prevalent vertebral fractures. A key 18-month randomized trial published in the New England Journal of Medicine compared teriparatide to alendronate in 428 patients with GIOP and found that teriparatide increased lumbar spine BMD by 7.2% vs. 3.4% for alendronate, with significantly fewer new vertebral fractures (0.6% vs. 6.1%, P=0.004) [12]. Teriparatide is the only GIOP therapy that directly stimulates new bone formation rather than simply slowing resorption.

Denosumab (60 mg subcutaneously every six months) is an alternative when bisphosphonates are contraindicated. A 12-month study in patients continuing glucocorticoids showed denosumab increased lumbar spine BMD by 3.8% compared to 0.8% with placebo [13]. The critical caveat with denosumab is rebound bone loss upon discontinuation. Patients who stop denosumab must transition to a bisphosphonate to prevent rapid BMD decline and vertebral fracture clustering [14].

Postmenopausal Women on Glucocorticoids: Compounded Risk

Postmenopausal women on long-term steroids face a dual assault on bone. Estrogen deficiency from menopause accelerates osteoclast-mediated resorption, while glucocorticoids simultaneously suppress osteoblast-mediated formation. The result is additive or synergistic bone loss that exceeds either condition alone.

The Endocrine Society Clinical Practice Guideline on osteoporosis in postmenopausal women recommends that glucocorticoid use be treated as a major risk factor equivalent to a prior fragility fracture when making treatment decisions [15]. A postmenopausal woman taking 5 mg/day prednisone with a T-score of -1.8 carries a fracture risk comparable to a woman with a T-score of -2.5 who is not on steroids.

For postmenopausal women at moderate risk, oral bisphosphonates remain first-line. For high-risk postmenopausal women (prior fracture, T-score at or below -2.5, or FRAX above threshold), teriparatide or abaloparatide should be considered as initial therapy rather than anti-resorptive agents, because anabolic agents build new bone rather than only slowing its loss [6]. After completing an anabolic course (typically 18 to 24 months), patients should transition to a bisphosphonate or denosumab to maintain gains.

Hormone replacement therapy (HRT) is not recommended as the primary bone-protective strategy in this population, though it may provide ancillary skeletal benefit in women already taking HRT for vasomotor symptoms [16].

Men with Hypogonadism: A Frequently Missed Population

Glucocorticoids suppress the hypothalamic-pituitary-gonadal axis, reducing testosterone production in men. Up to 50% of men on chronic prednisone therapy develop secondary hypogonadism, and testosterone deficiency independently accelerates bone loss [17]. Despite this, men on long-term steroids are screened for osteoporosis far less often than postmenopausal women.

The 2020 Endocrine Society guideline on male osteoporosis recommends checking total testosterone, DEXA, and FRAX in all men on glucocorticoids for three months or longer [18]. If testosterone is below 300 ng/dL, testosterone replacement therapy (TRT) should be considered as an adjunct to osteoporosis treatment, not a substitute for it. TRT alone does not reliably prevent glucocorticoid-induced fractures; bisphosphonate or anabolic therapy is still needed.

A prospective cohort study in Osteoporosis International found that men on chronic glucocorticoids had a 3.3-fold increased risk of vertebral fracture compared to age-matched controls, with the highest risk in men with concurrent testosterone levels below 200 ng/dL [19]. Treating the hypogonadism alongside the bone loss produces better outcomes than addressing either alone.

After Bariatric Surgery: Malabsorption Changes Everything

Patients who have undergone Roux-en-Y gastric bypass or biliopancreatic diversion and subsequently require long-term glucocorticoids face a particularly difficult clinical scenario. These procedures reduce the absorptive surface for calcium and vitamin D, often causing secondary hyperparathyroidism and accelerated bone turnover even without steroid exposure [20].

Adding glucocorticoids to a post-bariatric patient compounds existing calcium malabsorption. Oral bisphosphonates may also be poorly absorbed after bypass procedures. For these patients, the AACE recommends IV zoledronic acid or denosumab as preferred pharmacologic agents, since both bypass the GI tract entirely [21]. Calcium citrate (not carbonate) at doses of 1,500 to 2,000 mg/day in divided doses and vitamin D3 at 3,000 to 5,000 IU/day are typically required to maintain adequate serum levels [20].

DEXA monitoring should occur annually rather than every two years in post-bariatric patients on glucocorticoids, given the accelerated rate of bone loss. Serum 25-hydroxyvitamin D, intact PTH, and 24-hour urine calcium should be checked at least twice yearly to guide supplementation adjustments.

Patients on Aromatase Inhibitors: When Anti-Cancer Therapy Meets Steroids

Aromatase inhibitors (AIs) like letrozole and anastrozole, used in estrogen receptor-positive breast cancer, reduce circulating estrogen to near-undetectable levels. This causes rapid bone loss averaging 2 to 3% per year at the lumbar spine [22]. When a patient on an AI also requires long-term glucocorticoids (e.g., for autoimmune comorbidity), the skeletal risk compounds significantly.

The ASCO/Ontario Health guideline on bone health in breast cancer recommends baseline DEXA at AI initiation and repeat scanning at 1 to 2 year intervals [23]. Any patient on both an AI and glucocorticoids should be considered high-risk for fracture regardless of T-score and should receive pharmacologic bone protection.

Zoledronic acid 4 mg IV every six months has dual benefits in this population. It protects bone and, based on data from the ZO-FAST trial (N=1,065), may reduce breast cancer recurrence risk [24]. Denosumab 60 mg every six months is an alternative with strong BMD data in AI-treated patients (the ABCSG-18 trial showed a 50% reduction in clinical fractures with denosumab vs. placebo) [25]. The choice between these agents should account for renal function, treatment duration, and the need for a defined stopping point.

Monitoring and Adjusting Therapy Over Time

DEXA scanning should be repeated every one to two years in patients on ongoing glucocorticoid therapy, with shorter intervals for high-risk patients or those in the first year of treatment when bone loss is most rapid. A BMD decline of more than 3 to 5% per year despite treatment should prompt reassessment of adherence, vitamin D status, and consideration of switching to a more potent agent [6].

Serum markers of bone turnover (C-terminal telopeptide for resorption, procollagen type 1 N-terminal propeptide for formation) can provide earlier feedback on treatment response than DEXA alone. A significant drop in CTX within three to six months of starting a bisphosphonate confirms the drug is working. Conversely, persistently elevated CTX may indicate poor absorption or non-adherence [26].

When glucocorticoid therapy is discontinued, bone-protective treatment may be stopped if fracture risk has returned to low. Reassess with FRAX and DEXA three to six months after steroid cessation. Patients who received denosumab must transition to a bisphosphonate for at least 12 months after the last denosumab dose to prevent rebound vertebral fractures [14]. Abrupt denosumab discontinuation without bisphosphonate bridging has been associated with multiple vertebral compression fractures within 12 months of the last injection.